


AMENDMENT UNDER 37 CFR § 1.111
U.S. Appl. No. 09/368,670

(alkylcycloalkyl) optionally substituted with carboxyl; or heterocycle-C₁₋₆ alkyl [such as



and R_{11b} is C₁₋₆ alkyl substituted with carboxyl, (C₁₋₆ alkoxy)carbonyl or phenylmethoxycarbonyl; or C₇₋₁₆ aralkyl substituted on the aromatic portion with carboxyl, (C₁₋₆ alkoxy)carbonyl or phenylmethoxycarbonyl;

or R_{11a} and R_{11b} are joined to form a 3 to 7-membered nitrogen-containing ring optionally substituted with carboxyl or (C₁₋₆ alkoxy) carbonyl;


or

b) when Q is N-Y, a is 0 or 1, b is 0 or 1, [then] and

B is II, an acyl derivative of formula R₁₁-C(O)- or a sulfonyl of formula R₁₁-SO₂ wherein

R₁₁ is (i) C₁₋₁₀ alkyl optionally substituted with carboxyl[,] or C₁₋₆ alkanoyloxy [(e.g. AcOCH₂-),] ; C₁₋₆ alkoxy [(e.g. Boc),] ; or carboxyl substituted with 1 to 3 C₁₋₆ alkyl substituents;

(ii) C₃₋₇ cycloalkyl or C₄₋₁₀ alkylcycloalkyl, both optionally substituted with carboxyl




(C₁₋₆ alkoxy)carbonyl or phenylmethoxycarbonyl;

(iii) C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl optionally substituted with C₁₋₆ alkyl, hydroxy, or amino optionally substituted with C₁₋₆ alkyl; or

(iv) Het optionally substituted with C₁₋₆ alkyl, hydroxy, amino optionally substituted with

AMENDMENT UNDER 37 CFR § 1.111
U.S. Appln. No. 09/368,670

C₁₋₆ alkyl, or amido optionally substituted with C₁₋₆ alkyl,



R₆, when present, is C₁₋₆ alkyl substituted with carboxyl;

R₅, when present, is C₁₋₆ alkyl optionally substituted with carboxyl;
 [or] and


c) when Q is either CH₂ or N-Y, then

R₄ is C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl or C₄₋₁₀ (alkylcycloalkyl);

z is oxo or thioxo;


R₃ is C₁₋₁₀ alkyl optionally substituted with carboxyl, C₃₋₇ cycloalkyl or C₄₋₁₀ (alkylcycloalkyl);

W is a group of formula II:



wherein R₂ is C₁₋₁₀ alkyl or C₃₋₁₀ cycloalkyl optionally substituted with carboxyl or an ester or amide thereof; C₆ or C₁₀ aryl or C₇₋₁₆ aralkyl; or

W is a group of formula IIa:



wherein X is CH or N; and

R_{2a} is divalent C₃₋₄ alkylene which together with X and the carbon atom to which X and R_{2a} are attached form a 5- or 6-membered ring, said ring optionally substituted with OH; SH; NH₂; carboxyl; R₁₂; CH₂-R₁₂; OR₁₂; C(O)OR₁₂; SR₁₂; NHR₁₂ or NR₁₂R_{12a};

AMENDMENT UNDER 37 CFR § 1.111
U.S. Appl. No. 09/368,670

wherein R_{12} and R_{12a} are independently a saturated or unsaturated C_{3-7} cycloalkyl or C_{4-10} (alkyl cycloalkyl) being optionally mono-, di- or tri-substituted with R_{15} ,
or R_{12} and R_{12a} is a C_6 or C_{10} aryl or C_{7-16} aralkyl optionally mono-, di- or tri-substituted with R_{15} , or R_{12} and R_{12a} is Het or (lower alkyl)-Het optionally mono-, di- or tri-substituted with R_{15} ,

wherein each R_{15} is independently C_{1-6} alkyl; C_{1-6} alkoxy; amino optionally mono- or di-substituted with C_{1-6} alkyl; sulfonyl; NO_2 ; OH; SH; halo; haloalkyl; amido optionally mono-substituted with C_{1-6} alkyl, C_6 or C_{10} aryl, C_{7-16} aralkyl, Het or (lower alkyl)-Het; carboxyl; carboxy(lower alkyl); C_6 or C_{10} aryl, C_{7-16} aralkyl or Het, said aryl, aralkyl or Het being optionally substituted with R_{16} ;

wherein R_{16} is C_{1-6} alkyl; C_{1-6} alkoxy; amino optionally mono- or di-substituted with C_{1-6} alkyl; sulfonyl; NO_2 ; OH; SH; halo; haloalkyl; carboxyl; amide; or (lower alkyl)amide;

or X is CH or N; and R_{2a} is a divalent C_{3-4} alkylene which together with X and the carbon atom to which X and R_{2a} are attached form a 5- or 6-membered ring which in turn is fused with a second 5-, 6- or 7-membered ring to form a bicyclic system wherein the second ring is substituted with OR_{12a} wherein R_{12a} is C_{7-16} aralkyl;

R_{1a} is hydrogen, and R_4 is [C_{1-6} alkyl optionally substituted with thiol or halo; or R_1 is C_{2-6} alkenyl] the side chain of an amino acid selected from the group consisting of cysteine (Cys), aminobutyric acid (Abu), norvaline (Nva) and allylglycine (AlGly); or

R_{1a} and R_1 together form a 3- to 6-membered ring optionally substituted with R_{14} wherein R_{14} is C_{1-6} alkyl, C_{3-5} cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_6 aryl or C_{7-10} aralkyl all optionally substituted with halo; and

A is hydroxy or a [N-substituted amino] pharmaceutically acceptable salt of ester thereof; or C_{1-6} alkylamino, di(C_{1-6} alkyl)amino or phenyl- C_{1-6} alkylamino;

or a pharmaceutically acceptable salt or ester thereof.

AMENDMENT UNDER 37 CFR § 1.111
U.S. Appl. No. 09/368,670

In claim 2, line 2, delete "preferably".

In claim 4, line 1, delete "4" and insert --3--.

In claim 23, line 4 (page 153, line 1), delete "preferably";

line 8, delete "R₁₃, wherein".

Please cancel claim 29.

30. (Amended) The compound of formula I according to claim [29] 1, wherein R_{1a} is hydrogen and R₁ is the side chain of the amino acid selected from the group consisting of: cysteine (Cys), aminobutyric acid (Abu), norvaline (Nva), or allylglycine (AlGly).

In claim 33, line 2, delete "preferably".

Please cancel claim 36.

In claim 37, line 1, delete "36" and insert --1--.

In claim 41, line 1, delete "preferably";

line 2, delete "preferably".

65. (Amended) [Most preferably,] The compound of formula IB according to claim 64,
wherein R₁₄ is ethyl, vinyl or bromovinyl.

In claim 68, line 2, delete "preferably" and delete "C³⁻⁶" and insert --C₃₋₆--;

line 5, delete "preferably".

Please cancel claims 93-95, without prejudice.

Please add the following new claims 100-102:

-- 100. The compound of formula I according to claim 1, wherein R_{11a} is